Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 18 10:23AM ET
5.25
Dollar change
-0.02
Percentage change
-0.38
%
IndexRUT P/E- EPS (ttm)-1.63 Insider Own12.59% Shs Outstand98.63M Perf Week-11.76%
Market Cap521.01M Forward P/E- EPS next Y-1.75 Insider Trans-0.27% Shs Float86.74M Perf Month-25.00%
Income-160.93M PEG- EPS next Q-0.48 Inst Own103.91% Short Float19.01% Perf Quarter21.25%
Sales63.53M P/S8.20 EPS this Y-17.51% Inst Trans-2.83% Short Ratio5.84 Perf Half Y159.90%
Book/sh3.74 P/B1.41 EPS next Y9.20% ROA-26.56% Short Interest16.49M Perf Year-15.73%
Cash/sh3.18 P/C1.65 EPS next 5Y- ROE-37.76% 52W Range1.63 - 8.83 Perf YTD40.37%
Dividend Est.- P/FCF- EPS past 5Y-6.65% ROI-34.55% 52W High-40.54% Beta1.74
Dividend TTM- Quick Ratio8.48 Sales past 5Y87.14% Gross Margin71.22% 52W Low222.09% ATR (14)0.49
Dividend Ex-Date- Current Ratio8.48 EPS Y/Y TTM43.83% Oper. Margin-299.86% RSI (14)29.36 Volatility7.87% 7.55%
Employees181 Debt/Eq0.28 Sales Y/Y TTM-34.03% Profit Margin-253.30% Recom2.56 Target Price7.64
Option/ShortYes / Yes LT Debt/Eq0.26 EPS Q/Q22.82% Payout- Rel Volume0.28 Prev Close5.27
Sales Surprise8.97% EPS Surprise13.83% Sales Q/Q-96.22% EarningsFeb 26 AMC Avg Volume2.82M Price5.25
SMA20-20.70% SMA50-23.92% SMA20028.44% Trades Volume143,743 Change-0.38%
Date Action Analyst Rating Change Price Target Change
Mar-27-23Resumed Wells Fargo Equal Weight $6
Jan-24-23Downgrade H.C. Wainwright Buy → Neutral $115 → $7
Jan-06-23Downgrade Wedbush Outperform → Neutral $42 → $7
Jan-06-23Downgrade Truist Buy → Hold $46 → $7
Jan-06-23Downgrade Stifel Buy → Hold $107 → $5.30
Jan-06-23Downgrade Piper Sandler Overweight → Neutral $71 → $12
Jan-06-23Downgrade Cowen Outperform → Market Perform
Jan-06-23Downgrade BofA Securities Buy → Underperform $72 → $4
Jan-06-23Downgrade BMO Capital Markets Outperform → Market Perform $20 → $7
Jan-03-23Downgrade Guggenheim Buy → Neutral
Apr-06-24 02:17AM
Apr-04-24 11:30PM
Apr-03-24 08:00AM
Apr-02-24 04:01PM
Mar-27-24 11:30AM
08:44AM Loading…
Mar-19-24 08:44AM
Mar-05-24 04:01PM
Mar-01-24 08:09AM
08:00AM
Feb-27-24 09:16AM
08:07AM
Feb-26-24 05:10PM
04:35PM
04:08PM
04:01PM
09:21AM Loading…
Feb-21-24 09:21AM
Feb-19-24 10:00AM
Feb-15-24 08:00AM
Feb-02-24 04:01PM
Jan-30-24 07:54AM
Jan-29-24 02:53PM
Jan-08-24 08:00AM
Dec-22-23 12:00PM
Dec-18-23 02:58PM
Dec-13-23 05:00PM
Dec-08-23 11:30AM
Nov-09-23 01:18PM
Nov-08-23 06:18PM
04:08PM
04:01PM
08:00AM Loading…
Oct-25-23 08:00AM
Sep-15-23 06:01AM
Sep-07-23 11:30AM
Aug-31-23 08:00AM
Aug-29-23 07:30AM
Aug-09-23 12:12PM
11:04AM
Aug-08-23 05:15PM
04:11PM
04:01PM
Jul-28-23 08:00AM
Jul-22-23 08:35AM
Jul-01-23 10:33AM
Jun-16-23 03:53PM
Jun-14-23 06:42AM
Jun-08-23 11:30AM
Jun-07-23 11:30AM
Jun-04-23 08:27AM
Jun-02-23 11:31AM
May-31-23 08:00AM
May-25-23 10:49AM
May-08-23 06:05AM
May-04-23 11:59AM
11:22AM
May-03-23 05:15PM
04:11PM
04:01PM
12:00PM
Apr-27-23 10:03AM
Apr-26-23 10:02AM
Apr-24-23 08:00AM
Apr-12-23 07:20AM
Mar-30-23 11:30AM
Mar-27-23 09:00AM
Mar-03-23 04:01PM
Mar-02-23 09:18PM
05:30AM
Mar-01-23 09:59AM
Feb-28-23 05:15PM
04:01PM
Feb-27-23 09:31AM
Feb-13-23 08:00AM
Feb-06-23 09:55AM
Feb-02-23 09:46AM
Jan-30-23 07:33AM
Jan-28-23 01:30PM
Jan-19-23 09:35AM
Jan-17-23 06:27AM
Jan-06-23 01:55PM
10:54AM
10:27AM
08:49AM
Jan-05-23 05:00PM
07:40AM
Jan-03-23 09:35AM
Jan-02-23 08:39AM
Dec-13-22 08:00AM
Dec-12-22 07:30AM
Dec-10-22 02:46PM
10:00AM
Nov-09-22 03:55PM
Nov-07-22 08:00AM
Nov-04-22 04:01PM
Nov-03-22 05:35PM
04:01PM
09:00AM
Nov-01-22 10:01AM
Oct-31-22 08:49AM
Oct-27-22 10:03AM
Oct-24-22 04:01PM
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dulac Edward J IIIChief Financial OfficerMar 04 '24Sale7.772,44719,013101,479Mar 05 04:24 PM
Dulac Edward J IIIChief Financial OfficerJan 29 '24Sale5.001,8499,245103,926Jan 30 04:01 PM
Wolchko J ScottPresident and CEOJan 09 '24Sale4.3714,39162,889371,248Jan 10 04:29 PM
Valamehr BahramChief R&D OfficerJan 09 '24Sale4.3811,27149,367158,069Jan 10 04:30 PM
TAHL CINDYGeneral Counsel and SecretaryJan 09 '24Sale4.3710,87447,519142,361Jan 10 04:30 PM
Dulac Edward J IIIChief Financial OfficerJan 09 '24Sale4.377,02830,712105,775Jan 10 04:29 PM
Dulac Edward J IIIChief Financial OfficerJan 02 '24Sale3.665,18218,966112,803Jan 03 04:03 PM
Redmile Group, LLCDirectorDec 26 '23Buy3.7244,630166,02413,180,388Dec 28 09:30 PM
Dulac Edward J IIIChief Financial OfficerDec 18 '23Sale3.501,5855,548117,985Dec 19 04:01 PM
TAHL CINDYGeneral Counsel and SecretaryNov 09 '23Sale2.4024,36358,471153,235Nov 13 04:01 PM
Dulac Edward J IIIChief Financial OfficerAug 18 '23Sale2.804,71813,210119,570Aug 21 04:02 PM
Xu YuanDirectorAug 04 '23Sale3.716322,3459,302Aug 07 04:01 PM
Dulac Edward J IIIChief Financial OfficerJul 05 '23Sale4.835,18225,029124,288Jul 06 05:18 PM
Powl Brian T.Chief Commercial OfficerJul 05 '23Sale4.873,85418,76941,146Jul 06 05:19 PM
Xu YuanDirectorJun 14 '23Sale5.583,46019,3079,934Jun 15 04:05 PM
Redmile Group, LLCDirectorApr 21 '23Buy6.18256,6391,586,02913,135,758Apr 21 09:55 PM
Redmile Group, LLCDirectorApr 20 '23Buy5.9920,000119,80012,879,119Apr 21 09:55 PM